Asgard Therapeutics
@AsgardThx
Followers
271
Following
112
Statuses
158
Swedish biotech company exploring reprogramming as the next leap forward in cancer immunotherapy
Lund, Sverige
Joined December 2018
Join @AsgardThx at #ESMOIO2024 in Geneva! 🎤 Our Co-founder & CEO, @_CristianaPires speaks on Dec 13, 10:30–10:45, Room C. #AsgardTherapeutics #ImmunoOncology #ESMOIO2024
0
0
1
🌍 Join @AsgardThx at #BIOEUROPE2024 in Stockholm, Nov 4-6! 🗣️ Fireside Chat with CEO @_CristianaPires Topic: "All for You": Transforming patient care with Intratumoral Therapy 📅 Nov 5 | 🕒 12:30-13:00 | 📍 Exhibit Hall Stage Meet the Asgard team!
0
0
4
🚀 Meet @AsgardThx at two major events this October! Scientist Fritiof Åkerström will present at ESGCT 2024 on October 23rd, 8:30-10:00 AM in Rome! Also, connect with Xavier Catena at the AACR poster session on October 19th, 6:00-8:15 PM in Boston. #ESGCT2024 #AACR2024
0
0
5
✨We’re thrilled to announce that @AsgardThx is a finalist for the 2024 European Lifestars Awards! 🎉 Nominated for Biotech Company of the Year and Women-Led Business Leader of the Year with our CEO, @_CristianaPires! Looking forward to the awards on November 18 in London!
0
0
3
🚀 Meet @AsgardThx at CICON 2024 & ESMO Congress 2024! @CellReproLab will be presenting at CICON 2024 on Sept 9th, 5:15 PM. 🤝 Fábio Rosa will also attend. Meet with Xiaoli Huang, Project Director in Preclinical Pharmacology, at the ESMO Congress 2024 Let's connect!
0
0
7
1/23 We are excited to announce that our most recent study “In vivo dendritic cell reprogramming for cancer immunotherapy” was published in @ScienceMagazine. Here is a summary of what we discovered!
0
0
1
1/23 We are excited to announce that our most recent study “In vivo dendritic cell reprogramming for cancer immunotherapy” was published in @ScienceMagazine. Here is a summary of what we discovered!
0
0
3
📢 News! @AsgardThx together with @CellReproLab is happy to announce the preprint in bioRxiv “A cancer immunotherapy modality based on dendritic cell reprogramming in vivo” showcasing in vivo proof-of-concept for our lead program AT-108. Read on bioRxiv:
🌟1/7 Check out our new pre-print “A cancer #immunotherapy modality based on dendritic cell #reprogramming in vivo”, where we reprogram #tumor cells in situ to efficiently present antigens as type 1 conventional dendritic cells (cDC1s). How effective is it?
1
0
7
In addition, catch-up with new reprogramming insights from @CellReproLab! Our Head of Innovation, Filipe Pereira, and postdoc @CamilaVazquezE will speak on "Novel approaches to program and perturb cell fate" on Friday, July 12, 2024, 1:30-3:00 PM CEST.
✨ Excited for #ISSCR2024! Don't miss the concurrent session on "Novel approaches to program and perturb cell fate" featuring presentations by Filipe and @CamilaVazquezE. 📌 Join us on July 12, 13:30-15:00 at CCH – Congress Center Hamburg, Hall 4!
0
0
3
🚀 Excited to share highlights from our successful 3rd Annual SAB meeting in Lund! Discussions centered on ongoing CMC and IND enabling studies, as well as strategic regulatory and clinical pathways for lead program AT-108, all crucial steps towards being IND-ready by mid 2026.
1
1
9
Next stop – Boston! 🇺🇸 Join @AsgardThx Head of Research Fabio Rosa at 'Cancer Immunotherapy: From bench to bedside and back'. Catch his Poster Presentation on June 11, 12:15-1:45 p.m., Poster 2-9. Don’t miss out! #AsgardTherapeutics #CancerImmunotherapy #BostonEvent
0
0
4
@AsgardThx is heading back to Portugal! 🇵🇹 Join us at the VII iBiMED Symposium on May 24th at 14:30 at the University of Aveiro and meet our Co-founder and Head of Research Fabio Rosa! Don’t miss it! 🚀 #AsgardTherapeutics #Immunotherapy
0
2
6
Join us at the Lund Immunotalks Symposium: 'Diverse Path to Unlocking Immunity' on May 22nd, 13:00-18:30, Forum Medicum, BMC, Lund. 🌟 Exciting talks on cutting-edge immunology research! 🧬💥 Postdoc Xavier Catena will present at the poster session. ✨ Meet the @AsgardThx team!
0
0
4